menu
Home
About Us
»
« Back
Overview
Leadership
Board of Directors
Corporate Compliance
Contact
Research
»
« Back
Diseases and Conditions
Drug Development Pipeline
Drug Discovery
Clinical Trials
Publications
Investigator Initiated Studies
Partnerships
Careers
Citizenship
»
« Back
Social Responsibility
Scientist Development Program
Aclaris Support
Investors
»
« Back
Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts
Media resources
Contact us
Home
About Us
»
« Back
Overview
Leadership
Board of Directors
Corporate Compliance
Contact
Research
»
« Back
Diseases and Conditions
Drug Development Pipeline
Drug Discovery
Clinical Trials
Publications
Investigator Initiated Studies
Partnerships
Careers
Citizenship
»
« Back
Social Responsibility
Scientist Development Program
Aclaris Support
Investors
»
« Back
Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts
Recent updates
Feb 27, 2024
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Jan 16, 2024
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
Jan 10, 2024
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis